IL-21120033, CXCR7 agonist with significant efficacy in DSS-induced colitis model

March 5, 2025

Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.

BioWorld Science Conferences New compound Gastrointestinal Inflammatory

Today's news in brief

BioWorld

BioWorld briefs for April 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 15, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Capsules and tablets scattered over a world map

Biopharma tariffs becoming more than a threat

BioWorld

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...